Orthocell Share Price and Company Fundamentals
Last traded: Today at 5:10 AM
Orthocell Limited, a regenerative medicine company, develops and commercializes cell therapies and biological medical devices for the repair of various bone and soft tissue injuries in Australia and internationally. It offers Ortho Autologous Chondrocyte Implantation, a cartilage cell therapy for treatment of articular cartilage defects in the knee and ankle; Striate+, a resorbable collagen membrane used for guided bone and tissue regeneration in dental applications; and Remplir, a collagen scaffold used in peripheral nerve repair. The company also develops Collagen Medical Device platform products for nerve, tendon, and ligament repair; and Tendon Cell Therapy for rotator cuff and lateral epicondyle indications. Orthocell Limited was incorporated in 2006 and is headquartered in Murdoch, Australia.
Key Metrics
PE ratio
-
PB ratio
15.33
Dividend yield
-
Beta
-0.34
Market cap
$249.60M
Enterprise value
$205.74M
Company profile
| Industry / Sector | Biotechnology / Healthcare |
|---|---|
| Website | https://orthocell.com |
| Mailing address | Building 191 Murdoch University 90 South Street Murdoch WA 6150 Australia |
| Phone / Fax | 61 8 9360 2888 / 61 8 9360 2899 |
Dividends
More: Orthocell Dividend history, yield and payout ratio
Dividend yield
-
Dividend amount
$-
Payout ratio
0.00%
5Y Avg. yield
-%
Orthocell paid $- dividend and the ex-dividend date was -.The dividend payout ratio is 0.00%. The dividend payout ratio is defined as the amout of dividend paid divided by the earnings of the company.OCC dividend payout ratio is less than 70. This is ideal as it gives company room to grow the dividends and also the excess earnings can be invested in company for growth.
Company Executives
As of Feb 2026, following are the company executives and directors listed on Orthocell.
| Name | Title | Age | Total Pay |
|---|---|---|---|
| Mr. Paul Frederick Anderson | CEO, MD & Executive Director | 59 | |
| Mr. Jim Piper | Chief Financial Officer | ||
| Mr. Alex McHenry | Chief Operating Officer | ||
| Prof. Ming Hao Zheng | Chief Scientific Officer and Member of Medical & Scientific Advisory Board | ||
| John Walker | Vice President of Sales | ||
| Mr. Kevin Leach | Head of Marketing | 56 | |
| Mr. Tony Macintyre | Chief Technical Operations Officer | ||
| Mr. Adam Wood | Chief Commercial Officer | ||
| Mr. Peter Gordon Webse B.Bus, FCIS, FCPA, FGIA, M.A.I.C.D. | Company Secretary | 62 |
Profitability and management effectiveness
Profit margin
-113.45%
Operating margin
-155.86%
Return on assets
-26.42%
Return on equity
-89.70%
Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.
The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.
Valuation and Trading Info
The market capitalization of Orthocell is 249.60M and its enterprise value is 205.74M. The enterprise value to revenue ratio of OCC is 27.25. The enterprise value to EBITDA ratio of OCC is -16.21.
Companies similar to Orthocell (OCC)
Orthocell (ASX:OCC) Frequently Asked Questions
1. What is Orthocell's Stock Symbol?
Orthocell trades on ASX under the ticker symbol "OCC".
2. What is Orthocell's stock price today?
One share of OCC stock can currently be purchased for approximately $0.92.
3. How can I contact Orthocell?
Orthocell's mailing address is Building 191 Murdoch University 90 South Street Murdoch WA 6150 Australia. The company can be reached via phone at 61 8 9360 2888.
4. What is Orthocell's official website?
The official website of Orthocell is https://orthocell.com.